Primary Care Clinics in Paris, IL Accepting Medicare
7 Primary Care Clinics found. Showing 1 - 7
 Paris Clinic Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 721 E Court St, Paris, IL 61944 Phone: 217-463-0435 |
Paris Womens Health Care Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 721 E Court St, Paris, IL 61944 Phone: 217-463-0435 |
D.c.lim.md Inc. Family Medicine Medicare: Medicare Enrolled Practice Location: 230 S High St, Paris, IL 61944 Phone: 217-463-5412 Fax: 217-466-6994 |
Ezcare - Paris Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Phipps Lane, Paris, IL 61944 Phone: 217-463-4340 Fax: 217-463-4342 |
Hospital & Medical Foundation Of Paris, Inc Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 2200 S Main St, Paris, IL 61944 Phone: 217-463-4340 Fax: 217-463-4342 |
Nal Clinic Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Phipps Lane, Paris, IL 61944 Phone: 217-463-4340 |
Oakland Clinic Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 727 E Court St, Paris, IL 61944 Phone: 217-465-8411 Fax: 217-463-3184 |
News Archive
Study: 23% of doctors have negative perceptions on quality, effectiveness of generic drugs
A new study by researchers at Harvard, Brigham and Women's Hospital and CVS Caremark finds that 23 percent of doctors' have negative perceptions of the effectiveness and quality of generic drugs and that may lead to doctors prescribing unnecessarily expensive medications.
Teplizumab type I diabetes prevention study now enrolls younger children
A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old, following an FDA decision allowing the drug Teplizumab (anti-CD3) to be used in younger children.
TFAH applauds overall increase in disease prevention funding, expresses concern over CDC cuts
The Trust for America's Health (TFAH) applauds the President's budget for an overall increase in disease prevention funding, reflecting the new funds provided by the Prevention Fund from the Affordable Care Act (ACA), but expresses extreme concerns over the cuts to funding for core programs at the U.S. Centers for Disease Control and Prevention (CDC) and for emergency preparedness.
FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.
› Verified 7 days ago